Manufacturers report positive data for C21 from the ATTRACT clinical study in patients with COVID-19
In the study, this low molecular weight angiotensin II type 2 receptor agonist reduced the risk of needing oxygen at the end of treatment by 40%. Treatment also appeared to be well tolerated.
Source:
Biospace Inc.